Dantrolene prodrugs and methods of their use
The disclosure is directed to dantrolene prodrugs, compositions thereof, and methods of their use in the treatment of disease.
1. A ditromethamine salt of the compound of formula I-A
2. A pharmaceutical composition comprising the salt of claim 1 , and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , wherein the excipient comprises preservative, antioxidants, and mixtures thereof.
4. The pharmaceutical composition of claim 3 , wherein the preservative is selected from phenol, cresol, p-hydroxybenzoic ester, chlorobutanol, and mixtures thereof.
5. The pharmaceutical composition of claim 3 , wherein the antioxidant is selected from ascorbic acid, sodium pyrosulfite, palmitic acid, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and mixtures thereof.
6. The pharmaceutical composition of claim 2 , wherein the composition is a solution.
7. The pharmaceutical composition of claim 2 , wherein the compound of formula I-A is present at a concentration of about 1 mg/ml to about 400 mg/ml.
8. The pharmaceutical composition of claim 2 , further comprising a stabilizer.
9. The pharmaceutical composition of claim 2 , further comprising a buffer.
10. The pharmaceutical composition of claim 2 , wherein the composition has a pH of from about 3 to about 10.
11. The pharmaceutical composition of claim 2 , wherein the composition has an osmolarity from about 280 mOsm/L to about 310 mOsm/L.
12. A method of treating a treating a disorder responsive to dantrolene in a subject comprising administering to the subject a therapeutically effective amount of the salt of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disorder is malignant hyperthermia, chronic spasticity, exertional heat stroke, cardiac arrhythmias, tachycardia, atrial fibrillation, cardiac arrest, myocardial infarction, heart failure, myocardial injury, cardiomyopathy, central core disease, amyotrophic lateral sclerosis, rhabdomyolysis, Duchenne muscular dystrophy, ataxia, detrusor overactivity, overactive bladder, seizure, epilepsy, neuroleptic malignant syndrome, human stress disorder, Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, ischemia-reperfusion injury, neuronal reperfusion injury, hypoxia, cerebral aneurysm, subarachnoid hemorrhage, stroke, hyperthermia associated with drug abuse, hyperthermia associated with drug overdose, nerve agent exposure, nerve gas exposure, or acetylcholine accumulation.
13. The method of claim 12 , wherein the administration is intravenous administration.
14. The method of claim 12 , wherein the administration is intramuscular administration.
15. The method of claim 12 , wherein the administration is oral administration.
16. The method of claim 12 , wherein the administration is subcutaneous.
17. The method of claim 12 , wherein the administration is intranasal.
18. The method of claim 12 , wherein the administration is intraosseous.